ストックスクリーナーアプリを入手
3.43
2.83%
-0.10
アフターアワーズ：
3.41
-0.02
-0.58%
前日終値:
$3.53
開ける：
$3.49
24時間の取引高:
7.01M
Relative Volume:
1.15
時価総額：
$1.06B
収益：
$348.97M
当期純損益:
$5.86M
株価収益率:
204.17
EPS:
0.0168
ネットキャッシュフロー:
$13.69M
1週間 パフォーマンス:
-2.83%
1か月 パフォーマンス:
+20.77%
6か月 パフォーマンス:
-38.64%
1年 パフォーマンス:
-20.05%
1日の値動き範囲:
$3.41
$3.585
1週間の範囲:
$3.41
$3.94
52週間の値動き範囲:
$2.23
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Compare MNKD vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
3.43 | 1.09B | 348.97M | 5.86M | 13.69M | 0.0168 |
VRTX
Vertex Pharmaceuticals Inc
|
425.09 | 111.27B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
602.92 | 62.97B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.17 | 51.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.12 | 39.47B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.31 | 34.80B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-27 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-11-13 | 開始されました | Leerink Partners | Outperform |
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-10-10 | 開始されました | Leerink Partners | Outperform |
| 2025-07-16 | 再開されました | H.C. Wainwright | Buy |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-02-10 | 開始されました | Wedbush | Outperform |
| 2024-12-20 | 開始されました | Wells Fargo | Overweight |
| 2024-12-19 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-06-13 | 開始されました | Rodman & Renshaw | Buy |
| 2023-10-10 | 開始されました | Wedbush | Outperform |
| 2021-05-14 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | 開始されました | Oppenheimer | Outperform |
| 2019-10-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-05-14 | 開始されました | BTIG Research | Buy |
| 2019-03-04 | 開始されました | SVB Leerink | Outperform |
| 2019-02-22 | 開始されました | SVB Leerink | Outperform |
| 2018-02-28 | ダウングレード | Maxim Group | Hold → Sell |
| 2017-11-01 | ダウングレード | Maxim Group | Buy → Hold |
| 2017-10-10 | 開始されました | H.C. Wainwright | Buy |
| 2017-10-06 | 繰り返されました | Maxim Group | Buy |
| 2017-08-11 | 開始されました | Maxim Group | Buy |
| 2016-05-10 | 繰り返されました | Piper Jaffray | Underweight |
| 2016-05-10 | 繰り返されました | RBC Capital Mkts | Underperform |
| 2016-01-06 | 繰り返されました | Piper Jaffray | Underweight |
| 2016-01-06 | 繰り返されました | RBC Capital Mkts | Underperform |
| 2015-11-04 | ダウングレード | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | ダウングレード | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-05-11 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2015-05-11 | 繰り返されました | MLV & Co | Hold |
| 2015-04-16 | 繰り返されました | RBC Capital Mkts | Outperform |
すべてを表示
Mannkind Corp (MNKD) 最新ニュース
FDA approves MannKind’s Afrezza inhaled insulin for children with diabetes - Investing.com
FDA clears MannKind (NASDAQ: MNKD) Afrezza use in children 6 and older - Stock Titan
MannKind Corp stock (US5638651064): Afrezza pediatric FDA approval and share price weakness draw foc - AD HOC NEWS
MNKD stock eyes best month since 2022 ahead of FDA decision on pediatric diabetes treatment - MSN
symbol__ Stock Quote Price and Forecast - CNN
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market - Yahoo Finance
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - Stocktwits
FDA approves Afrezza for children and adolescents with diabetes - Managed Healthcare Executive
US FDA approves MannKind's inhaled insulin for children - Reuters
MannKind Corporation (MNKD) Receives FDA Approval for Pediatric Use of Afrezza - GuruFocus
MannKind (MNKD) Receives FDA Nod for Pediatric Use of Afrezza - GuruFocus
Inhaled insulin for kids: MannKind hosts call on new Afrezza use - Stock Titan
MannKind wins FDA approval for inhaled insulin for children with type 1, type 2 diabetes - MassDevice
US FDA approves MannKind’s inhaled insulin for children By Reuters - Investing.com
MannKind’s Afrezza approved for children with diabetes - Investing.com
MannKind Corporation Announces FDA Approval of Afrezza® Inhalation Powder for Pediatric Use in Type 1 and Type 2 Diabetes - Quiver Quantitative
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes - The Manila Times
FDA approves first inhaled mealtime insulin for kids 6+ - Stock Titan
MNKD Technical Analysis | Trend, Signals & Chart Patterns | MANNKIND CORP (NASDAQ:MNKD) - ChartMill
MannKind Corporation Files Form 8-K Announcing Regulatory Update and Company Information (May 27, 2026) - Minichart
FDA drops MannKind (NASDAQ: MNKD) Afrezza pulmonary malignancy trial demand - Stock Titan
MNKD Stock Eyes Best Month Since 2022 Ahead Of FDA Decision On Pediatric Diabetes Treatment - Yahoo Finance
MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits
Top Companies in Diabetes Drug Therapy MarketAbbott - openPR.com
MannKind to Present at Jefferies Global Healthcare Conference - Yahoo Finance
New data on inhaled insulin for kids as FDA weighs Afrezza - Stock Titan
MannKind Corporation 8-K Filing Details Board Election Results and Company Information (May 2026) - Minichart
Director Michael A. Friedman awarded 82,781 MannKind (MNKD) restricted stock units - Stock Titan
MannKind director (MNKD) awarded stock and RSUs, updates holdings - Stock Titan
MannKind (MNKD) director Jennifer Grancio granted 82,781 restricted stock units - Stock Titan
Director Sabrina Kay (NASDAQ: MNKD) awarded 82,781 MannKind RSUs - Stock Titan
MannKind shareholders elect directors and approve proposals at annual meeting - Investing.com
MannKind (NASDAQ: MNKD) reports 2026 annual meeting voting results - Stock Titan
MannKind (MNKD) HR chief adds 33,898 shares under stock purchase plan - Stock Titan
MNKD stock records biggest single-day gains in over 5 years, breaches a key technical milestone – what’s driving this rally? - MSN
MannKind Corp stock (US5638651064): inhaled insulin specialist draws attention after recent business - AD HOC NEWS
MannKind Corp stock (US5638651064): focus on Afrezza growth and partnership pipeline - AD HOC NEWS
FY2026 EPS Estimates for MannKind Increased by HC Wainwright - MarketBeat
MannKind Corp. (MNKD) Reports Q1 2026 Total Revenues of $90.2M - Insider Monkey
MannKind Corp stock (US5638651064): respiratory drug specialist in focus after latest quarterly upda - AD HOC NEWS
5 Best NASDAQ Stocks Under $5 to Buy Right Now - Insider Monkey
MNKD (NASDAQ) amendment shows RSU resale filing via Morgan Stanley - Stock Titan
MannKind Corp stock (US5638651064): Biopharma innovator in inhaled therapies - AD HOC NEWS
Mannkind director Steven Binder sells $55,732 MNKD stock - Investing.com
MannKind EVP David Thomson sells $9,978 in company stock By Investing.com - Investing.com India
MannKind EVP David Thomson sells $9,978 in company stock - Investing.com India
Mannkind director Steven Binder sells $55,732 MNKD stock By Investing.com - Investing.com Nigeria
MANNKIND CORP (MNKD) officer has shares withheld to cover RSU taxes - Stock Titan
MannKind (MNKD) EVP trades shares under pre-set Rule 10b5-1 plan - Stock Titan
Mannkind Corp (MNKD) 財務データ
収益
当期純利益
現金流量
EPS
2.89%
大文字化:
|
ボリューム (24 時間):